| Project/Area Number |
20591618
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
YAMAMOTO Yuzo Akita University, 医学系研究科, 教授 (70281730)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUME Makoto 秋田大学, 医学部, 講師 (00372326)
UCHINAMI Hiroshi 秋田大学, 医学部, 講師 (40400486)
|
|---|
| Research Collaborator |
GOTO Toru 秋田大学
YOSHIOKA Masato 秋田大学
WATANABE Go 秋田大学
IWASAKI Wataru 秋田大学
KIKUCHI Isao 秋田大学
SATO Kohei 秋田大学
NAKAGAWA Yasuhiko 秋田大学
KUDOH Kazuhiro 秋田大学
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 胆道外科学 / 胆道癌 / 補助化学療法 / ゲムシタビン / 薬物代謝動態 / 手術侵襲 / 肝切除 / 認容性 / 有害事象 / 代謝 / 肝切除術 / 個別化治療 / 周術期薬理学 / 薬剤忍容性 / 薬物動態の個体内変動 / 肝切徐術 |
|---|
| Research Abstract |
In rat partial hepatectomy model, gemcitabine administration of recommended dose resulted in higher blood concentration (1.24 times) than non-hepatectomized rat on POD 2. Ad-ministration of 80% dose could achieve the blood concentration similar to that in nonhepatectomized rat received recommended dose. However, after completion of liver regeneration on POD 14, recommended dose was necessary to achieve the expecting blood concentration. On the other hand, in the clinical setting of partial hepatectomy, administration of recommended dose of gemcitabine did not cause an excessive blood concentration in spite of reduced liver volume. However, the incidence of an adverse effect relating to bone marrow suppression was higher in the patients after hepatectomy. These result suggest that reduced tolerance for gemcitabine following hepatectomy does not simply responsible for gemcitabine pharmacodynamics in the blood.
|
